Home › Trials › NCT04958720

Registry for esophageal and gastric cancer data collection

AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer

Fundación Sociedad Española de Oncologia Médica · NCT04958720

This study is collecting information from medical records of adults with esophageal and gastric cancer to help researchers learn more about these diseases and improve patient care.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages18 Years to 100 Years
SexAll
SponsorFundación Sociedad Española de Oncologia Médica (other)
Locations38 sites (Alicante, Alicante and 37 other locations)
Trial IDNCT04958720 on ClinicalTrials.gov

What this trial studies

This observational study aims to create a comprehensive database for esophageal and gastric cancer patients, facilitating epidemiological and clinical research. Data will be collected retrospectively from medical records of adult patients diagnosed with these cancers, ensuring rigorous data management and analysis. The initiative is designed to enhance understanding of these cancers, optimize patient management, and improve the quality of scientific publications in the field.

Who should consider this trial

Good fit: Ideal candidates include adult patients aged 18 and older diagnosed with esophageal, gastroesophageal junction, or gastric carcinoma.

Not a fit: Patients who cannot provide necessary medical information for database completion will not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with esophageal and gastric cancer.

How similar studies have performed: Other similar registries have shown success in enhancing cancer research and patient care, indicating a positive precedent for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
* Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.

Exclusion Criteria:

* A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.

Where this trial is running

Alicante, Alicante and 37 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Esophageal Cancer, Gastric Cancer, Gastroesophageal junction cancer, Surgery, Chemotherapy, Radiotherapy, Antitargeted drug, Inmunotherapy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.